Additionally, SGLT-2 inhibitors may further lower BNP and NT-proBNP levels by inhibiting myocardial fibrosis and improving cardiac remodeling.[43] The KCCQ is a crucial tool for assessing the quality of life in HF patients, encompassing dimensions such as symptom assessment and functional status. The gene discussed is SLC5A2; the disease is Myocardial fibrosis.